Last updated on May 2019

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis


Brief description of study

The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.

Clinical Study Identifier: NCT03129100

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.